IntroDuctIon
The heart is the earliest organ to form in the developing embryo, providing the basis for a functional circulation as other organ systems develop. Emerging bioengineering and biotechnology approaches for studying the formation of the mesoderm and its cellular lineages provide us with a great opportunity to develop new insights into this complex developmental process. In particular, hPSCs provide an ideal system with which to study these questions because they (i) are of human origin, (ii) are scalable, (iii) allow for the use of advanced molecular biology tools for analysis, and (iv) provide a simplified system for studying cell-fate choices in early development.
During embryogenesis, cell-fate decisions are coordinated by gradients of cytokines and morphogens that allow for differentiation and organization of multiple cell types into complex tissues 1 . The capacity to direct these complex fate choices is mediated by critical spatiotemporally orchestrated cues required to direct specific cell fates and cell subtypes. Well-described anterior-posterior morphogen gradients principally involving activin/nodal and BMP4 are required for developing a polarized axis during gastrulation [2] [3] [4] [5] . This polarization of mesoderm gives rise to the heterogeneous cell types of the cardiovascular system, including cardiomyocytes and those of the endocardium, vascular endothelium, and the hematopoietic system (Fig. 1) . These three lineages are differentiated by lineage-specific modulation of key signaling pathways, including the vascular endothelial growth factor (VEGF) signaling pathway for ECs and Wnt signaling inhibition for cardiomyocytes.
Advantages, limitations, and alternative methods
Studies using hPSCs, by our laboratory 6, 7 and others 8, 9 , have contributed substantially to knowledge about mechanisms of human mesodermal patterning. The protocol presented here enables the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post facto enrichment, which can disturb cell regulatory states and reduce viability and yield. hPSC polarization toward cardiogenic mesoderm allows for the derivation of both cardiomyocytes and ECs, whereas hPSC polarization toward hemogenic mesoderm gives rise to only blood-forming ECs.
Although efforts have been made to define conditions for polarization of lateral plate mesoderm from embryonic stem cells in vitro [3] [4] [5] 10, 11 , there has been limited success in translating these observations into protocols to generate high-purity definitive populations. Studies have shown that polarization of hPSCs during specification of mesoderm provides developmental cues that are deterministic for generating definitive cell types 6, 10 . This is in keeping with a history of studies showing that developmental specification of definitive lineages occurs as early as gastrulation, at which point gene programs required to direct one lineage also simultaneously actively repress gene programs for other lineages [10] [11] [12] [13] .
hPSCs have been used extensively in efforts to derive human endothelium [14] [15] [16] [17] . Despite substantial effort, attempts to generate high-purity endothelium from hPSCs have met with modest success, with efficiencies ranging from 5 to 30% cells positive for Human pluripotent stem cells (hpscs) provide a valuable model for the study of human development and a means to generate a scalable source of cells for therapeutic applications. this protocol specifies cell fate efficiently into cardiac and endothelial lineages from hpscs. the protocol takes 2 weeks to complete and requires experience in hpsc culture and differentiation techniques. Building on lessons taken from early development, this monolayer-directed differentiation protocol uses different concentrations of activin a and bone morphogenetic protein 4 (BMp4) to polarize cells into mesodermal subtypes that reflect mid-primitive-streak cardiogenic mesoderm and posterior-primitive-streak hemogenic mesoderm. this differentiation platform provides a basis for generating distinct cardiovascular progenitor populations that enable the derivation of cardiomyocytes and functionally distinct endothelial cell (ec) subtypes from cardiogenic versus hemogenic mesoderm with high efficiency without cell sorting. ecs derived from cardiogenic and hemogenic mesoderm can be matured into >90% cD31 + /Ve-cadherin + definitive ecs. to test the functionality of ecs at different stages of differentiation, we provide methods for assaying the blood-forming potential and de novo lumen-forming activity of ecs. to our knowledge, this is the first protocol that provides a common platform for directed differentiation of cardiomyocytes and endothelial subtypes from hpscs. this protocol yields endothelial differentiation efficiencies exceeding those of previously published protocols. Derivation of these cell types is a critical step toward understanding the basis of disease and generating cells with therapeutic potential.
lineage markers, including VE-cadherin, kinase insert domain receptor (KDR; also known as vascular endothelial growth factor receptor 2), and CD34 (refs. 16,18,19) . As such, most widely implemented protocols currently require cell sorting to enrich ECs to purity 16, 17 . This is problematic because it shows that control of cell-fate choices directed toward the endothelial lineage-despite being well understood during embryogenesis-are not efficiently controlled in hPSC-directed differentiation.
The current protocol provides important strides forward for hPSC-directed differentiation into the cardiovascular lineages. First, this protocol provides a common differentiation platform for deriving cardiac and endothelial lineages through simple modulation of activin A and BMP4 concentrations. Second, developmental studies have shown distinct origins and mechanisms for specifying endothelial subtypes such as endocardial, vascular, and lymphatic ECs [20] [21] [22] [23] [24] [25] . To this end-using an approach of polarizing hPSC mesoderm at the onset of differentiation-this protocol provides the first approach for controlling EC differentiation from cardiogenic versus hemogenic mesoderm. Third, unlike other protocols reported so far, we have identified conditions for directing differentiation of all lineages to >90% purity without any sorting steps. We have previously provided extensive characterization of these mesoderm populations using gene expression, proteomics, and analysis of endogenous Wnt/β-catenin signaling activity 6 .
Despite these advances, the current approach sustains ongoing limitations with existing reagents for differentiation. In the first place, the protocol requires the use of Matrigel, B-27 supplement, and recombinant proteins, which are prone to batch effects, making differentiation variable, requiring lot testing. Second, this protocol is limited in its impact on the cardiac differentiation protocols, given the extensiveness of simple small-molecule-based approaches that have been optimized [26] [27] [28] . This component of the protocol is helpful for studies that aim to decipher how cardiomyocyte versus EC lineage potential is specified from cardiogenic mesoderm.
Although this protocol is an advancement in the field for studying developmental lineage decisions in cardiac and endothelial differentiation, other protocols provide important complementary methods for using these cell types in a range of applications that include primary vascular plexus formation using hPSCderived pericytes 16 , vasculature xenografts in zebrafish in vivo 16 , and the generation of definitive cell types in a scalable manner for therapeutics 29 . Other protocols also provide methods for using hPSCs to derive pericytes, smooth muscle cells, arterial versus venous ECs, and cardiomyocytes that can be used in coordination with the methods outlined here 16, 17, 27, 28, 30 .
Applications
This protocol provides opportunities to study fundamental questions about lineage choices, advance approaches for tissue engineering, and derive a broader scope of cell types for cardiovascular therapeutic applications. The common platform for deriving mesodermal subtypes provides an opportunity to study mechanisms underlying polarization of mesoderm and fate choices that govern lineage specification from common progenitor populations. The generation of ECs from cardiogenic mesoderm also provides an opportunity to study the process of endocardial development and valve formation that could lead to commercial applications for therapeutic outcomes. In an effort to re-create the lineages of the heart from hPSCs, this method for derivation of ECs from cardiogenic mesoderm couples well with existing protocols for generating vascular ECs, pericytes, smooth muscle cells, cardiomyocytes, epicardial cells, and fibroblasts 16, 17, 30, 31 . This protocol's high efficiency of differentiation is a major advance, providing a scalable source of cells for applications such as tissue engineering, cell therapy, disease modeling, and drug discovery.
Overview of the procedure and experimental design
In this report, we use developmental cues in a monolayer differentiation approach to generate different cardiovascular subtypes, reproducibly achieving >90% purity of all lineages without sorting (an overview of this protocol is provided in Fig. 2) . The efficient control of differentiation of diverse variable that influences differentiation efficiency. We therefore tested three different plating densities (Fig. 3a) and determined the impact on lineage specification into cardiac and EC types, as shown throughout this protocol.
Polarization of lineages into cardiogenic versus hemogenic mesoderm (
Step 13A and B). This protocol provides a method for generating polarized mesoderm by induction of differentiation under varying concentrations of activin A (day 0) and BMP4 (day 1) in RPMI medium with B-27 supplement minus insulin. We also make use of the approach optimized by Zhang et al. 32 , in which Matrigel is added to the induction medium in an effort to facilitate signaling cues for epithelial-to-mesenchymal transition, which occurs during gastrulation. However, not all cell lines require Matrigel for efficient differentiation. In keeping with developmental gradients of activin A that direct polarization of mesoderm, cardiogenic mesoderm (mid-primitive streak) is derived under conditions of 100 ng ml −1 activin A, whereas hemogenic mesoderm (posterior-primitive streak) is derived under conditions of 50 ng ml −1 activin A. RPMI medium with B-27 supplement minus insulin is used in both cases 6 . We have previously shown that similar results are achieved using doses <50 ng ml −1 (ref. 6). During exposure to activin A (17-18 h), cells appear to 'tighten', leaving acellular regions throughout the plate (Fig. 3b) . On day 1, the medium is changed to RPMI medium with B-27 supplement minus insulin, containing the Wnt/β-catenin signaling agonist CHIR-99021. Cardiogenic mesoderm is derived from cultures exposed to 5 ng ml −1 BMP4, whereas hemogenic mesoderm is derived from cultures exposed to 40 ng ml −1 BMP4. We have empirically shown that mesoderm is formed on day 2, based on time-course assays of gene expression 6, 7 . Under the conditions described, the cells transition from a compact state on day 1 to a dispersed monolayer throughout the plate on day 2 (Fig. 3c) . Table 1 provides primers for quantitative RT-PCR for analysis of pan-mesoderm genes, as well as those that show lineagespecific expression in cardiogenic versus hemogenic mesoderm. Cardiomyocyte purity is assessed at day 14 using FACS to detect cardiac Troponin T-positive (cTnT + ) cells. KDR + /CD34 + expression at day 5 is used as an indicator of purity during early stages of pan-endothelial differentiation. 13A-14A) . The efficiency of cardiac differentiation from pluripotency is directly related to the ability to specify mid-streak cardiogenic mesoderm as opposed to the more anterior-streak endoderm or posterior-streak hemogenic mesoderm. As we have shown previously, deviating from precise specification of cardiogenic mesoderm has marked effects on the efficiency of cardiomyocyte differentiation 6 . We also show that the density of cells has major implications for proper specification of high-purity derivatives ( Fig. 4a; Supplementary Methods) .
Cardiac differentiation (Steps
Proper dosage of Wnt/β-catenin signaling has been shown to be one of the major determinants of specification into the cardiac lineage 6, 7, 9, 28, 33, 34 . Although Wnts are required for mesoderm specification, their signaling subsequently must be inhibited to direct cells into the cardiac lineage 7, 9, 28, 34 . We therefore add an exogenous tankyrase inhibitor, XAV-939, on day 3 of differentiation to reinforce this key step during cardiac progenitor cell specification. Previous work has suggested that cardiac progenitor cells, which emerge on day 5 of differentiation, can be assessed for purity on the basis of KDR/PDGFRα expression 3, 35 . Using our protocol, we have found a statistically significant (P < 0.05) negative correlation with KDR + /PDGFRα + cells at day 5 versus the efficiency of cardiac differentiation at day 14, and therefore we do not advocate for this phenotyping approach 6 . Table 1 provides primers for amplifying genes involved in specification of the cardiac progenitor cell, including NKX2-5, GATA4, TMEM88, ISL1, and MYL4.
As the protocol progresses past the progenitor cell stage, we make use of insulin in a stage-dependent manner during cardiac differentiation. This approach has been supported by studies showing that insulin is inhibitory before cardiac progenitor cell specification but is required for definitive cardiomyocyte development 36 . Accordingly, RPMI medium is changed on day 7 to include the B-27 supplement containing insulin. Beating cardiomyocytes can be seen as early as day 7. Cells progressively mature to definitive cardiomyocytes by day 14, at which point they are ~90% cTnT + as ascertained by FACS analysis and express high levels of Nkx2-5, α-actinin, and the junctional protein connexin 43 ( Fig. 4b) . Box 1 describes methods for staining cardiomyocytes for quantification of cTnT and smooth muscle actin (SMA) by FACS analysis. SMA is expressed in immature cardiomyocytes but is replaced by cardiac α-actin (ACTC1), as cardiomyocytes become more mature. Table 1 provides primers for amplifying genes expressed in definitive cardiomyocytes, including the myofilament genes TNNT2 and MYH6, the transcription factor TBX5, and the calcium-handling genes ATP2a2 and RYR2. For further phenotyping, we recommend previous protocols that have provided detailed methods for characterization of cardiomyocytes by immunohistochemistry 27 . As with other lineages outlined in the protocol, this protocol does not require purification (e.g., using selection or sorting [37] [38] [39] [40] [41] ) at any point to achieve high-purity cardiomyocytes.
Differentiation of ECs from mesodermal subtypes (Steps 13 and 14B).
Previous work has shown a requirement for VEGF and active Wnt/β-catenin signaling in the development of endothelium 42, 43 . We tested a wide range of culture conditions adapted from previous differentiation protocols 14, 18, 19, 44, 45 to determine optimal parameters for differentiation of the endothelium, building from our monolayer-directed mesodermal differentiation platform ( Supplementary Fig. 1 ). This yielded some interesting observations. First, as compared with the marked effects observed with cardiac differentiation, we found that the seeding densities tested at the onset of differentiation did not markedly influence the purity of ECs generated by this protocol (Fig. 5) . Second, in contrast to current embryoid body protocols 14, 18, 19, 44 , high levels of VEGF stimulation are required to direct endothelial differentiation in a monolayer format (Supplemental Fig. 1; Fig. 5 ).
Third, we determined that cells remain responsive to VEGF stimulation between days 2 and 3 of differentiation but lack 
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cardiac progenitor cells Fig. 2 ). Last, we found that augmenting Wnt/β-catenin pathway activity after mesoderm induction using the agonist CHIR-99021 was inhibitory to endothelial differentiation at all doses tested (Supplementary Fig. 1 ). Among a wide range of conditions vetted, we describe here a unique protocol that generates >90% pure ECs from cardiogenic and hemogenic mesoderm. ECs generated from cardiogenic mesoderm have poor blood-forming capacity and express markers of endocardial endothelium, whereas ECs generated from hemogenic mesoderm (e.g., those expressing NFATC1) have robust blood-forming potential and express markers of the extraembryonic mesoderm (e.g., HAND1) 6 . In contrast to cardiomyocyte differentiation, which is highly sensitive to specification of hPSCs through cardiogenic mesoderm, endothelium is known to form from all mesodermal origins 1, 46 . We have similarly shown this with hPSC endothelial differentiation 6 .
Hemogenic endothelium
On day 2, when hPSCs have formed mesoderm subtypes (cardiogenic or hemogenic), EC differentiation is directed by changing the medium to StemPro-34, containing VEGF, BMP4, bFGF, ascorbic acid, and monothioglycerol. Cells remain in this medium until day 5. Endothelial purity is assayed at day 5 by FACS analysis for KDR + / CD34 + cells; however, markers of definitive endothelium, including VE-cadherin and CD31, are also evident at this time point ( Fig. 5;  Supplementary Fig. 3 ; Supplementary Methods). Box 1 describes methods for staining ECs for analysis of KDR and CD34 by FACS analysis. Table 1 outlines primers for quantitative RT-PCR analysis of pan-endothelial markers (e.g., SCL) versus those that specifically identify endocardial endothelium (e.g., NFATC1) versus bloodforming endothelium (e.g. GATA1, RUNX1, and HAND1).
Findings during mouse development have shown that endocardial endothelium has very limited, transient hematopoietic activity, whereas the posterior-streak-derived hemogenic endothelium is the primary source for blood formation in development 47 . We have shown that the hPSC endothelium derived from cardiogenic mesoderm exhibits modest blood-forming activity, largely giving rise to primitive erythroid derivatives, whereas hPSC-ECs derived from hemogenic mesoderm have the capacity for both the erythroid and myeloid lineages 6 . By contrast, the hPSC cardiac progenitor cells have no blood-forming activity 7 . As described in Box 1, we use phenotyping of day 5 cells initially to characterize primitive erythroid cell types based on the percentage of CD43 + / CD235a + cells ( Fig. 6a; Supplementary Fig. 3 ; Supplementary Methods) 6 . As a secondary assay, we provide a brief description in Box 2 for the blood colony-forming assay in methylcellulose (Fig. 6b) . Methods for differentiation into later-stage hematopoietic derivatives have been described elsewhere 6, 7, 48 .
To mature cells into definitive ECs, day 5 cells are passaged for expansion in endothelial growth medium (EGM) containing VEGF, bFGF, and CHIR-99021 for an additional 5-10 d. We tested a number of matrix substrates to determine their effect on maturation of ECs, including Matrigel, fibronectin, and gelatin, and found no difference (Fig. 7) . We found that differentiation under these conditions led to near 99% CD31 + ECs from both cardiogenic and hemogenic mesoderm without requiring sorting (Fig. 7a,b) .
In our previous work, we have shown marked differences in the functionality of EC subtypes in the context of engineered microvascular networks 6 . Given the technically specialized nature of this method 49 , we provide a more classic approach for assaying EC functionality on the basis of lumen formation in collagen gels (Box 3). Previous protocols have also provided extensive details for performing immunohistochemistry for endothelial markers, as well as a variety of additional functional end points for assaying ECs in vitro and in vivo 16, 17 . Human pluripotent stem cells ! cautIon Appropriate national laws and institutional regulatory board guidelines must be followed, and informed consent should be obtained from human subjects. The cell lines used should be regularly checked to ensure that they are authentic and that they are not infected with mycoplasma. The cell lines that we have successfully used with this protocol include RUES2 (Rockefeller University), IMR90 (WiCell), and WTC11 (University of San Francisco). (Fig. 5) . 
Box 2 | Primitive hematopoietic colony-forming assays
5% (vol/vol) FBS-PBS (500 ml)
In a sterile hood, mix 25 ml of FBS with 475 ml of PBS. The solution can be stored at 4 °C for up to 6 months.
0.1% (vol/vol) Gelatin-H 2 O(500 ml)
In a sterile hood, mix 10 ml of 5% (vol/vol) Gelatin solution with 490 ml of Millipore water. Filter using a 500-ml sterile filter. If the 5% (vol/vol) stock gelatin solution is congealed, warm it in a 37 °C water bath until it has dissolved. The solution can be stored at 4 °C for up to 6 months. 30× Matrigel-DMEM/F12 (20 ml) In a sterile hood, add 10 ml of 4° C DMEM/F12 to one vial (10 ml) of 60× Matrigel at 4 °C and resuspend. ! cautIon Matrigel is very sensitive to changes in temperature and may gel if it is not aliquotted quickly. Divide the solution into (3 ml) aliquots and freeze them at −20° C. The solution can be stored at 4 °C for up to 6 months. 10% (vol/vol) trypsin-Versene solution(10 ml) In a sterile hood, gently mix 1 ml of 2.5% (vol/vol) trypsin at 4 °C with 9 ml of Versene at 37 °C in a 15-ml conical tube. We do not recommend storing this solution; use it fresh.
Stop solution In a sterile hood, gently mix equal volumes of FBS and DMEM/F12 with 200 units ml −1 of DNase 1. The solution can be stored at 4 °C for up to 1 month. 0.75% Saponin in 5% (wt/vol) FBS-PBS (500 ml) In a sterile hood, mix 3.75 g of dry saponin with 500 ml of 5% (wt/vol) FBS-PBS. ! cautIon Saponin is a very dangerous, light chemical that must be weighed in a fume hood. After thoroughly mixing, filter the solution using a 500-ml sterile filter. The solution can be stored at 4 °C for up to 6 months. mTeSR1 basal medium + 1× mTeSR1 supplement + 1 mg ml −1 penicillin-streptomycin (500 ml) In a sterile hood, add the contents of one 5× mTeSR1 supplement vial (100 ml) to 400 ml of mTeSR1 basal medium and mix thoroughly to make mTeSR1 medium. Then, mix 5 ml of 10 mg ml −1 penicillin-streptomycin with 495 ml of the mTeSR1 medium. The medium can be stored at 4 °C for up to 4 weeks. The mTeSR1 medium used in this protocol includes the supplement. RPMI + 100 ng (or 50 ng) ml −1 activin A + 1× B-27 without insulin + 1× Matrigel In a sterile hood, add appropriate volumes (see the PROCEDURE for protocols) of 10 µg ml −1 activin A, 50× B-27 without insulin, and 30× Matrigel-DMEM/F12 solution to RPMI to achieve your total desired volume (see Table 2 for respective plate format volumes). We do not recommend storing this solution. RPMI + 5 ng (or 40 ng) ml −1 BMP4 + 1 mM CHIR-99021 + 1× B-27 without insulin In a sterile hood, add appropriate volumes (see the PROCEDURE for protocols) of 10 µg ml −1 BMP4, 25 mM CHIR-99021, and 50× B-27 minus insulin to RPMI to achieve your total desired volume (see Table 2 for respective plate format volumes). We do not recommend storing this solution.
RPMI + 1 mM XAV 939 + 1× B-27 without insulin
In a sterile hood, add appropriate volumes (see the PROCEDURE for protocols) of 10 mM XAV 939 and 50× B-27 minus insulin to RPMI to achieve your total desired volume (see Table 2 for respective plate format volumes). We do not recommend storing this solution.
RPMI + 1× B-27 minus (or plus) insulin (510 ml)
In a sterile hood, add one vial (10 ml) of 50× B-27 minus (or plus) insulin to 500 ml of RPMI. We do not recommend storing this solution. StemPro + 4 × 10 −4 M MTG + 2 mM l-glutamine + 50 mg ml −1 ascorbic Acid + 10 ng ml −1 BMP4 + 5 ng ml −1 bFGF + 300 ng ml −1 VEGF (25 ml) In a sterile hood, add appropriate volumes (see the PROCEDURE for protocols) of 1 M MTG, 200 mM l-glutamine, 5 mg ml −1 ascorbic acid, 10 µg ml −1 BMP4, 10 µg ml −1 bFGF, and 500 µg ml −1 VEGF to StemPro medium to achieve your total desired volume (see Table 2 for respective plate format volumes). We do not recommend storing this solution. EBM + EGM supplements In a sterile hood, thoroughly mix the EGM supplements from the BulletKit with EBM (500 ml). The medium can be stored at 4 °C for up to 2 weeks. The EGM referred to in the PROCEDURE is EBM with EGM supplements already added. EGM + 20 ng ml −1 VEGF + 20 ng ml −1 bFGF + 1 mM CHIR-99021 In a sterile hood, add appropriate volumes (see the PROCEDURE for protocols) of 500 µg ml −1 VEGF, 10 µg ml −1 bFGF, and 25 mM CHIR-99021 to EGM medium to achieve your total desired volume (see Table 2 for respective plate format volumes). We do not recommend storing this solution.
EQUIPMENT SETUP Matrigel-coated plates (25 ml) In a sterile hood, gently mix 0.83 ml of Matrigel-DMEM/F12 30× with 24.17 ml of DMEM/F12 in a 50-ml conical tube. Immediately add Matrigel in DMEM/F12 at a volume of 6 ml per 10-cm plate or 500 µl per well of a 24-well plate. Allow the Matrigel to set overnight at 4 °C. The Matrigel-coated plates can be stored at 4 °C for up to 3 weeks. 
2|
Remove hPSCs, such as RUES2s (Rockefeller University), from liquid N 2 and thaw rapidly. ! cautIon Appropriate national laws and institutional regulatory board guidelines must be followed, and informed consent should be obtained from human subjects. All necessary consent forms were acquired for hPSCs used in this study.
3|
Transfer the cells to a 50-ml conical tube containing 5 ml of mTeSR1 medium with 1 µg ml −1 penicillin-streptomycin.
4|
Centrifuge the cell suspension at 200g for 5 min at room temperature. Aspirate and discard the supernatant with a sterilized Pasteur pipette.
5| Using a 5-ml pipette, gently resuspend the cell pellet in mTeSR1 medium + 10 µM Y27632 + 1 µg ml −1 penicillinstreptomycin. Limit the number of triturations. Count the cells. After aspirating the liquid from the warmed Matrigel-coated plate, slowly add cells to the medium for a plating density of ~1.2 × 10 4 cells cm −2 . Put the plate into a 37 °C, 5% CO 2 incubator. Move the plate in quick, short, to-and-fro and side-to-side motions to evenly distribute the cells across the surface and then leave them undisturbed overnight.  crItIcal step Including the Rho kinase inhibitor Y-27632 is very important for high hPSC recovery after freezing and thawing.
6|
The next day, aspirate the medium and replace it with fresh 37 °C mTeSR1 medium containing 1 µg ml −1 penicillinstreptomycin. Repeat this medium replacement daily until the cells are ready for passage (Step 7). 
10|
Aspirate the liquid from a room-temperature Matrigel-coated plate. Add mTeSR1 + 10 µM Y27632 + 1 µg ml −1 penicillin-streptomycin to the plate. Next, slowly add a fraction of the cell suspension from Step 9 to the plate to achieve a plating density of ~1.2 × 10 4 cells cm −2 . Place the plate in the incubator. Move the plate in quick, short, to-and-fro and side-to-side motions to evenly distribute the cells across the surface of the plate. Leave the plate undisturbed overnight.
11|
The next day, aspirate the medium and replace it with fresh 37 °C mTeSR1 + 1 µg ml −1 penicillin-streptomycin. Repeat this medium replacement daily until the cells are 75-85% confluent or any one individual colony is wider than the diameter of the viewing field with a 10× objective (the amount of time this takes depends on the split ratio); daily monitoring is necessary. Pluripotent cell culture can be maintained by repeating Steps 7-11 before moving to the next steps for monolayer differentiations of hPSCs. • tIMInG Steps 1-5, thawing hPSCs: 30 min
Monolayer differentiation setup for hpscs
Step 6, daily maintenance of hPSCs: 4 d Steps 7-11, passaging hPSCs using Versene: 20 min, plus 4 d for maintenance
Step 12, monolayer differentiation setup for hPSCs: 20 min
Step 13A, cardiogenic mesoderm differentiation: 2 d
Step 13B, hemogenic mesoderm differentiation: 2 d
Step 14A, directed differentiation into cardiomyocytes: 12 d
Step 14B, directed differentiation of endothelium subtypes: 3-12 d
antIcIpateD results
This protocol provides an efficient methodology for the generation of high-purity definitive mesodermal subtypes from hPSCs, including cardiomyocytes and endothelial cells. Upon induction of differentiation with activin A and BMP4, cells should show marked morphological changes as they transit from pluripotency to mesoderm (Fig. 4b) , with marked differences in gene expression (tables 1 and 3) consistent with lineage specification into cardiogenic versus hemogenic mesoderm. Under conditions of Wnt inhibition from cardiogenic mesoderm, differentiation should show time-dependent activation of cardiac transcription factor and myofilament genes by day 5 of differentiation. Beating should be observed by days 7-10, with differentiation achieving ~90% cTnT + cells by day 14 (Fig. 4) .
For endothelial differentiation, cells should progress to day 5 of differentiation, achieving ~90% KDR + /CD34 + cells with gene expression patterns that distinguish cardiogenic versus hemogenic EC lineages. Evidence of primitive hematopoiesis should be seen almost entirely in ECs derived from hemogenic mesoderm, based on the presence of CD43 + /CD235a + cells (Fig. 6a) . Similarly, functional blood-forming assays in methylcellulose should show very little blood-forming potential in ECs derived from cardiogenic mesoderm, whereas ECs derived from hemogenic mesoderm should show robust primitive 
